natgillin/translations-raw huggingface dataset:
Sildenafil had no effect on saquinavir pharmacokinetics (see section 4.2).
Sildenafil ni vplival na farmakokinetiko sakvinavirja (glejte poglavje 4.2).
Nicorandil is a hybrid of potassium channel activator and nitrate.
Nikorandil je mešanec aktivatorja kalijevih kanalčkov in nitrata.
There are no data on the interaction of sildenafil and non-specific phosphodiesterase inhibitors such as theophylline or dipyridamole.
O interakcijah sildenafila in nespecifičnih zaviralcev fosfodiesteraze, kot sta teofilin ali dipiridamol, ni podatkov.
This medicine allows an erection to last long enough for you to satisfactorily complete sexual activity.
To zdravilo omogoča erekcijo, ki traja dovolj časa, da se zadovoljivo konča spolni odnos.
Agents for the treatment of erectile dysfunction, including sildenafil, should not be used in men for whom sexual activity is inadvisable (e.g. patients with severe cardiovascular disorders such as unstable angina or severe cardiac failure).
Zdravil za zdravljenje erektilne disfunkcije, vključno s sildenafilom, ne smejo uporabljati moški, za katere spolna dejavnost ni priporočljiva (npr. bolniki s hudimi kardiovaskularnimi motnjami, kot sta nestabilna angina pektoris ali hudo srčno popuščanje).
ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Germany
ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Nemčija
In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite.
Pri normalnih zdravih moških prostovoljcih ni bilo opaziti učinkov azitromicina (tri dni po 500 mg na dan) na AUC, Cmax, tmax, konstanto hitrosti eliminacije ali na poznejši razpolovni čas sildenafila oz. njegovega glavnega metabolita v obtoku.
PVdC/PVC/Aluminium blisters.
Pretisni omoti iz PVdC/PVC/aluminija.
Sildenafil is an oral therapy for erectile dysfunction.
Sildenafil je peroralno zdravilo za zdravljenje erektilne disfunkcije.
The following patient groups were represented: elderly (19.9%), patients with hypertension (30.9%), diabetes mellitus (20.3%), ischaemic heart disease (5.8%), hyperlipidaemia (19.8%), spinal cord injury (0.6%), depression (5.2%), transurethral resection of the prostate (3.7%), radical prostatectomy (3.3%).
Zastopane so bile naslednje skupine bolnikov: starostniki (19,9 %), bolniki z zvišanim krvnim tlakom (30,9 %), sladkorno boleznijo (20,3 %), ishemično boleznijo srca (5,8 %), hiperlipidemijo (19,8 %), poškodbo hrbtenjače (0,6 %), depresijo (5,2 %), transuretralno resekcijo prostate (3,7 %) in po radikalni prostatektomiji (3,3 %).
When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP.
Ko je aktivirana pot NO/cGMP, kot se to zgodi pri spolni stimulaciji, zavrtje PDE5 s sildenafilom zviša raven cGMP v corpusu cavernosumu.
Based on these pharmacokinetic results co-administration of sildenafil with ritonavir is not advised (see section 4.4) and in any event the maximum dose of sildenafil should under no circumstances exceed 25 mg within 48 hours.
Glede na te farmakokinetične ugotovitve sildenafila ni priporočljivo uporabljati z ritonavirjem (glejte poglavje 4.4), največji odmerek sildenafila pa nikakor ne sme preseči 25 mg v 48 urah.
Sildenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1).
Sildenafil ima vazodilatacijske lastnosti, ki povzročijo blago in prehodno znižanje krvnega tlaka (glejte poglavje 5.1).
Taking these medicines with Sildenafil ratiopharm could seriously affect your blood pressure.
Jemanje teh zdravil skupaj z zdravilom Sildenafil ratiopharm lahko močno vpliva na krvni tlak.
This is most likely to occur within 4 hours post sildenafil dosing (see sections 4.2 and 4.4).
Največja verjetnost, da se to zgodi, je v 4 urah po odmerku sildenafila (glejte poglavji 4.2 in 4.4).
In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis.
V naravnih okoliščinah, tj. ob spolni stimulaciji, z zvečanjem dotoka krvi v penis obnovi okvarjeno erektilno funkcijo.
Sildenafil ratiopharm contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Zdravilo Sildenafil ratiopharm vsebuje zdravilno učinkovino sildenafil, ki spada v skupino zdravil, ki jih imenujemo zaviralci fosfodiesteraze tipa 5 (PDE5).
The pharmacokinetics of sildenafil in patients with severely impaired hepatic function have not been studied.
Farmakokinetika sildenafila pri bolnikih s hudo okvaro delovanja jeter ni raziskana.
Sildenafil ratiopharm is not indicated for use by women.
Zdravilo Sildenafil ratiopharm ni indicirano za uporabo pri ženskah.
In particular, sildenafil has greater than 4,000-fold selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility.
Še posebno pa je selektivnost sildenafila več kot 4.000-krat večja za PDE5 kakor za PDE3 - za cAMP specifično izoobliko fosfodiesteraze, ki sodeluje pri nadzoru krčljivosti srca.
Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.
Simptomi vključujejo nenadno zadihanost, težave pri dihanju ali omotico, oteklino očesnih vek, obraza, ustnic ali grla.
Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 80 mg/dl.
Sildenafil (50 mg) ni stopnjeval hipotenzivnih učinkov alkohola pri zdravih prostovoljcih, ki so imeli srednjo največjo koncentracijo alkohola v krvi 80 mg/dl.
If you experience any of the following serious side effects stop taking Sildenafil ratiopharm and seek medical help immediately:
Če opazite katerega od naslednjih resnih neželenih učinkov, prenehajte jemati zdravilo in nemudoma poiščite zdravniško pomoč:
What you need to know before you take Sildenafil ratiopharm
Kaj morate vedeti, preden boste vzeli zdravilo Sildenafil ratiopharm
(≥ 1/100 and
(≥ 1/100 in
The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated: severe hepatic impairment, hypotension (blood pressure < 90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases).
Varnost sildenafila ni raziskana pri naslednjih podskupinah bolnikov, pri katerih je njegova uporaba zato kontraindicirana: huda okvara jeter, hipotenzija (krvni tlak < 90/50 mmHg), nedavna možganska kap ali miokardni infarkt in znane dedne degenerativne bolezni mrežnice, npr. retinitis pigmentosa (manjši del teh bolnikov ima genetske motnje mrežničnih fosfodiesteraz).
In single dose volunteer studies of doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased.
V študijah enega odmerka pri zdravih prostovoljcih so bili neželeni učinki pri odmerkih do 800 mg podobni tistim pri nižjih odmerkih, bili pa so pogostejši in izrazitejši.
Plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil.
Koncentracija tega presnovka v plazmi je približno 40 % koncentracije sildenafila.
In addition, initiation of sildenafil at a dose of 25 mg should be considered (see sections 4.4 and 4.5).
Poleg tega je treba razmisliti o uvedbi sildenafila v odmerku 25 mg (glejte poglavji 4.4 in 4.5).
These additional blood pressure reductions were of a similar magnitude to those seen when sildenafil was administered alone to healthy volunteers (see section 5.1).
To dodatno znižanje krvnega tlaka je bilo po velikosti podobno kot pri dajanju sildenafila samega zdravim prostovoljcem (glejte poglavje 5.1).
These symptoms usually occur within 4 hours of taking Sildenafil ratiopharm.
Navadno se pojavijo 4 ure po zaužitju zdravila Sildenafil ratiopharm.
- if you suffer from any of the following disorders or symptoms, as you may experience more side effects: an abnormality of the red blood cells (sickle cell anaemia); cancer of the blood (leukaemia); a cancer of the bone marrow (multiple myeloma); any disease or deformity of the penis.
če imate katero koli naslednjo motnjo ali simptome, saj boste imeli morda več neželenih učinkov: abnormalnost rdečih krvničk (anemijo srpastih celic), krvnega raka (levkemijo), rak kostnega mozga (multipli mielom), katero koli bolezen ali deformacijo penisa;
Take 1 film-coated tablet of Sildenafil ratiopharm about 1 hour before sexual activity.
Eno filmsko obloženo tableto zdravila Sildenafil ratiopharm vzemite približno eno uro pred spolnim odnosom.
When sildenafil and doxazosin were administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports of patients who experienced symptomatic postural hypotension.
Ko so sildenafil in doksazosin sočasno uporabili pri bolnikih, pri katerih bolezen ni napredovala pri zdravljenju z doksazosinom, so poročali o redkih primerih simptomatske posturalne hipotenzije.
In a separate RigiScan study, sildenafil was still able to produce an erection in response to sexual stimulation 4-5 hours post-dose.
V posebni študiji z RigiScanom so ugotovili, da lahko sildenafil povzroči erekcijo kot odziv na spolno stimulacijo še 4 do 5 ur po odmerku.
Due to age-differences in plasma protein binding, the corresponding increase in free sildenafil plasma concentration was approximately
Zaradi starostno pogojenih razlik v vezavi na beljakovine v plazmi so se plazemske koncentracije prostega sildenafila ustrezno zvečale za približno 40 %.
A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes, before pharmacological treatment is considered.
Pred odločitvijo za farmakološko zdravljenje je treba z anamnezo in telesnim pregledom diagnosticirati erektilno disfunkcijo in ugotoviti morebitne osnovne vzroke zanjo.
At maximum recommended doses, there is an 80-fold selectivity over PDE1, and over 700-fold over PDE2, 3, 4, 7,
V največjih priporočenih odmerkih je selektivnost 80-kratna v primerjavi s PDE1 in prek 700-kratna v primerjavi s PDE2, 3, 4, 7, 8, 9, 10 in 11.
Sildenafil ratiopharm with food, drink and alcohol When this medicine is taken with food, it may take a little longer for Sildenafil ratiopharm to work.
Uporaba zdravila Sildenafil ratiopharm skupaj s hrano, pijačo in alkoholom Če to zdravilo vzamete skupaj s hrano, bo morda trajalo malo dlje, da bo zdravilo Sildenafil ratiopharm začelo učinkovati.
Doses of 200 mg did not result in increased efficacy but the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, altered vision) was increased.
Odmerek 200 mg ni bil bolj učinkovit, zvečala pa se je pogostnost neželenih učinkov (glavobola, zardevanja, omotice, dispepsije, zamašenega nosu, sprememb vida).
Take ½ or 1 film-coated tablet of Sildenafil ratiopharm as prescribed by your doctor about 1 hour before sexual activity.
Vzemite polovico filmsko obložene tablete ali eno filmsko obloženo tableto zdravila Sildenafil ratiopharm, kot vam je predpisal vaš zdravnik, približno eno uro pred spolnim odnosom.
In a penile plethysmography (RigiScan) study of fasted patients, the median time to onset for those who obtained erections of 60% rigidity (sufficient for sexual intercourse) was 25 minutes (range 12-37 minutes) on sildenafil.
V študiji s pletizmografijo penisa (RigiScan) in uporabo sildenafila na prazen želodec je bil mediani čas do začetka delovanja pri bolnikih, ki so dosegli erekcijo s 60-% čvrstostjo (zadostno za spolni odnos), 25 minut (razpon: od 12 do 37 minut).
If you feel dizzy, or if your vision or hearing is affected after taking Sildenafil ratiopharm, do not drive or operate any tools or machines.
Če ste po zaužitju zdravila Sildenafil ratiopharm omotični ali je prizadet vid ali sluh, ne vozite ali upravljajte z orodji ali stroji.
Population pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, cimetidine).
Analiza podatkov populacijske farmakokinetike v kliničnih študijah je pokazala, da se očistek sildenafila zmanjša pri sočasni uporabi zaviralcev CYP3A4 (npr. ketokonazola, eritromicina, cimetidina).
In volunteers with mild to moderate renal impairment (creatinine clearance = 30-80 mL/min), the pharmacokinetics of sildenafil were not altered after receiving a 50 mg single oral dose.
Pri prostovoljcih z blago do zmerno okvaro ledvic (očistek kreatinina = 30 do 80 ml/min) farmakokinetika sildenafila po enkratnem 50-mg peroralnem odmerku ni bila spremenjena.
In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in the visual tests conducted (visual acuity, Amsler grid, colour discrimination simulated traffic light, Humphrey perimeter and photostress).
V majhni s placebom nadzorovani študiji pri bolnikih s potrjeno zgodnjo starostno degeneracijo makule (n = 9) sildenafil v enkratnem 100-mg odmerku ni imel pomembnega vpliva na preiskave vida (ostrina vida, Amslerjeva mrežica, ločevanje barv na simuliranem semaforju, Humphreyev perimeter in fotostres).
The side effects reported in association with the use of sildenafil are usually mild to moderate and of a short duration.
Neželeni učinki o katerih poročajo v zvezi z uporabo tega zdravila so ponavadi blagi do zmerni in se pojavijo za kratek čas.
The safety and efficacy of combinations of sildenafil with other PDE5 Inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil, or other treatments for erectile dysfunction have not been studied.
Varnost in učinkovitost kombinacije sildenafila z drugimi zaviralci PDE5, drugimi zdravili proti pljučni arterijski hipertenziji (PAH), ki vsebujejo sildenafil, ali z drugimi zdravili za zdravljenje erektilne disfunkcije nista raziskani, zato uporaba takih kombinacij ni priporočena.
*Reported during post-marketing surveillance only **Visual colour distortions: Chloropsia, Chromatopsia, Cyanopsia, Erythropsia and Xanthopsia ***Lacrimation disorders: Dry eye, Lacrimal disorder and Lacrimation increased
*O tem so poročali v obdobju trženja **Motnje zaznavanja barv: kloropsija, kromatopsija, cianopsija, eritropsija in ksantopsija ***Motnje solzenja: suhe oči, motnje solzenja in povečano solzenje
Sildenafil is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).
Sildenafil je kontraindiciran pri bolnikih, ki so izgubili vid na enem očesu zaradi nearteritične anteriorne ishemične optične nevropatije (NAION), tudi če ta dogodek ni bil povezan s predhodnim jemanjem zaviralcev PDE5 (glejte poglavje 4.4).
Although no increased incidence of adverse events was observed in these patients, when sildenafil is administered concomitantly with CYP3A4 inhibitors, a starting dose of 25 mg should be considered.
Čeprav pri teh bolnikih niso ugotovili večje pogostnosti neželenih učinkov, je pri sočasni uporabi sildenafila z zaviralci CYP3A4 priporočljivi začetni odmerek 25 mg.
The major circulating metabolite results from N-demethylation of sildenafil.
Glavni presnovek v obtoku je posledica N-demetilacije sildenafila.
Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (e.g. aortic stenosis, hypertrophic obstructive cardiomyopathy), or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure.
Med bolnike z zvečano občutljivostjo za vazodilatatorje spadajo bolniki z obstrukcijo iztoka iz levega prekata (npr. z aortno stenozo, hipertrofično obstruktivno kardiomiopatijo) ali z redkim sindromom multiple sistemske atrofije, ki se kaže kot huda okvara avtonomnega uravnavanja krvnega tlaka.
Grapefruit juice is a weak inhibitor of CYP3A4 gut wall metabolism and may give rise to modest increases in plasma levels of sildenafil.
Sok grenivke je šibek zaviralec presnove s CYP3A4 v črevesni steni in lahko povzroči rahlo zvišanje plazemske ravni sildenafila.
Do not throw away any medicines via wastewater.
Zdravila ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
Healthy, elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 90% higher plasma concentrations of sildenafil and the active N-desmethyl metabolite compared to those seen in healthy younger volunteers (18-45 years).
Zdravi starejši prostovoljci (stari 65 let ali več) so imeli manjši očistek sildenafila, zato so imeli koncentracijo sildenafila in aktivnega N-desmetilnega presnovka v plazmi približno 90 % večjo kot mlajši zdravi prostovoljci (od 18 do 45 let).
Agents for the treatment of erectile dysfunction, including sildenafil, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).
Zdravila za zdravljenje erektilne disfunkcije, vključno s sildenafilom, je treba previdno uporabljati pri bolnikih z anatomskimi deformacijami penisa (npr. z angulacijo, kavernozno fibrozo ali Peyroniejevo boleznijo) in bolnikih z določenimi boleznimi, ki povzročajo nagnjenost k priapizmu (npr. s srpastocelično anemijo, multiplim mielomom ali levkemijo).
If this occurs during or after intercourse: Get in a semi-sitting position and try to relax.
• Se namestite v polsedeči položaj in se poskusite sprostiti.
In order to reduce the probability of these symptoms occurring, you should start taking Sildenafil ratiopharm only when you are already well controlled on a regular daily dose of your alpha blocker.
Da zmanjšate verjetnost pojava teh simptomov, začnite zdravilo Sildenafil ratiopharm jemati šele, ko je zdravljenje z rednim dnevnim odmerkom antagonista adrenergičnih receptorjev alfa dobro nadzorovano.
Symptoms may include severe peeling and swelling of the skin, blistering of the mouth, genitals and around the eyes, fever.
Simptomi lahko vključujejo hudo lupljenje in otekanje kože, mehurčke na ustih, spolovilu in okoli oči, povišano telesno temperaturo.
- The other ingredients are: microcrystalline cellulose, hypromellose, croscarmellose sodium, magnesium stearate, calcium hydrogen phosphate anhydrous, talc, macrogol 6000, titanium dioxide, iron oxide red.
Druge sestavine zdravila so: mikrokristalna celuloza, hipromeloza, premreženi natrijev karmelozat, magnezijev stearat, brezvodni kalcijev hidrogenfosfat, smukec, makrogol 6000, titanov dioksid, rdeči železov oksid.
Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates).
Posebne študije interakcij niso bile izvedene za vsa zdravila, populacijske farmakokinetične analize niso pokazale vpliva na farmakokinetiko sildenafila pri sočasnem zdravljenju z zdravili iz skupine zaviralcev CYP2C9 (npr. tolbutamid, varfarin, fenitoin) ali zaviralcev CYP2D6 (npr. selektivni zaviralci prevzema serotonina, triciklični antidepresivi), tiazidi in sorodnimi diuretiki, diuretiki Henlejeve zanke in diuretiki, ki varčujejo s kalijem, zaviralci ACE, zaviralci kalcijevih kanalčkov, antagonisti adrenergičnih receptorjev beta ali induktorji metabolizma s CYP450 (npr. rifampicin ali barbiturati).
This is most likely to occur within 4 hours post sildenafil dosing.
Največja verjetnost, da se to zgodi, je v 4 urah po odmerku sildenafila.
Initiation of sildenafil at a dose of 25 mg should be considered (see section 4.2).
Razmisliti je treba o uvedbi sildenafila v odmerku 25 mg (glejte poglavje 4.2).
The N-desmethyl metabolite is further metabolised, with a terminal half-life of approximately 4 h.
N-desmetilni presnovek se presnovi naprej; končni razpolovni čas je približno 4 ure.
In a study of the haemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70% stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7% and 6% respectively compared to baseline.
V študiji hemodinamičnih učinkov enkratnega peroralnega 100-mg odmerka sildenafila pri 14 bolnikih s hudo boleznijo koronarnih arterij (> 70-% stenoza vsaj ene koronarne arterije) se je srednji sistolični tlak v mirovanju v primerjavi z izhodiščem znižal za 7 %, povprečni diastolični tlak v mirovanju pa za 6 %.
Effects of other medicinal products on sildenafil In vitro studies
Učinki drugih zdravil na sildenafil
Sildenafil ratiopharm 25 mg film-coated tablets EU/1/09/603/001
Sildenafil ratiopharm 25 mg filmsko obložene tablete EU/1/09/603/001
The postulated mechanism for this change in colour discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina.
Domnevni mehanizem spremembe razločevanja barv je zavrtje PDE6, ki sodeluje pri fototransdukcijski kaskadi v mrežnici.
In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh A and B) sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment.
Pri prostovoljcih z blago do zmerno cirozo jeter (Child-Pugh A in B) je bil očistek sildenafila zmanjšan, kar je povzročilo zvečanje AUC (84 %) in Cmax (47 %) v primerjavi s prostovoljci primerljive starosti brez okvare jeter.
- Seizures or fits - this occurs rarely.
Konvulzije ali napadi - to se zgodi redko.
In healthy volunteers receiving sildenafil (100 mg single dose), less than 0.0002% (average 188 ng) of the administered dose was present in ejaculate 90 minutes after dosing.
Pri zdravih prostovoljcih, ki so dobili sildenafil (en 100-mg odmerek), je bilo v ejakulatu 90 minut po uporabi manj kot 0,0002 % (povprečno 188 ng) uporabljenega odmerka.
The mean maximum decreases in supine systolic blood pressure following 100 mg oral dosing of sildenafil was 8.4 mmHg.
Srednje največje znižanje sistoličnega krvnega tlaka leže je bilo po 100-mg peroralnem odmerku sildenafila 8,4 mmHg.
What Sildenafil ratiopharm is and what it is used for
Kaj je zdravilo Sildenafil ratiopharm in za kaj ga uporabljamo
In volunteers with severe renal impairment (creatinine clearance < 30 mL/min), sildenafil clearance was reduced, resulting in mean increases in AUC and Cmax of 100% and 88% respectively compared to age-matched volunteers with no renal impairment.
Pri prostovoljcih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) se je očistek sildenafila zmanjšal, to pa je povzročilo povprečno zvečanje AUC za 100 % in Cmax za 88 % v primerjavi s prostovoljci primerljive starosti brez okvare ledvic.
After oral dosing of sildenafil AUC and Cmax increase in proportion with dose over the recommended dose range (25-100 mg).
Po peroralni uporabi sildenafila se AUC in Cmax v priporočenem razponu odmerkov (od 25 do 100 mg) večata sorazmerno z odmerkom.
You may find that this medicine takes longer to work if you take it with a heavy meal.
Če to zdravilo vzamete s težkim obrokom, bo morda minilo dalj časa, preden bo delovalo.